Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 01, 2014
- Source ID
- 10.1016/j.bbmt.2013.10.023
Entities
People
- Alan M. Miller
- Armin Ghobadi
- Biju George
- Bipin N Savani
- Bruce M. Camitta
- Celalettin Ustun
- Corey S. Cutler
- César O. Freytes
- Daniel J Weisdorf
- David I. Marks
- Edmund K Waller
- Edwin M. Horwitz
- Erica D. Warlick
- Frédéric Baron
- Geoffrey L. Uy
- Gerard Socie
- Görgün Akpek
- Harry C. Schouten
- Hillard M Lazarus
- Jane L. Liesveld
- Jean-yves Cahn
- John Koreth
- Kristjan Paulson
- Mark R Litzow
- Martin Bornhäuser
- Mary Eapen
- Mary J. Laughlin
- Matthew Seftel
- Mitchell S Cairo
- Mitchell Sabloff
- Olle Ringden
- Rammurti T. Kamble
- Ravi Vij
- Robert Peter Gale
- Ruta Brazauskas
- Usama Gergis
- Vikram Mathews
- Wael Saber
- Xiaobo Zhong
- Yi-Bin Chen
Organizations
- ARIAD Pharmaceuticals
- Amgen
- Blue Cross Blue Shield Association
- Elevance Health, Inc.
- GSK
- Kiadis Pharma (Netherlands)
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck & Co.
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Osiris Therapeutics
- Otsuka (United States)
- Roche (United States)
- Sanofi-Aventis
- Seagen
- Sigma-Tau Pharmaceuticals (United States)
- StemCyte
- Swedish Orphan Biovitrum
- Tarix Orphan (United States)